BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394-419. [PMID: 30070375 DOI: 10.1002/hep.30145] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 21.5] [Reference Citation Analysis]
Number Citing Articles
1 Pedersen MR, Mayo MJ. Managing the Symptoms and Complications of Cholestasis. Clin Liver Dis (Hoboken) 2020;15:120-4. [PMID: 32257123 DOI: 10.1002/cld.901] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Corpechot C. Clinical Trials in PBC Going Forward. Semin Liver Dis 2019;39:e1-6. [DOI: 10.1055/s-0039-1687852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Jang JS, Juran BD, Cunningham KY, Gupta VK, Son YM, Yang JD, Ali AH, Enninga EAL, Sung J, Lazaridis KN. Single-cell mass cytometry on peripheral blood identifies immune cell subsets associated with primary biliary cholangitis. Sci Rep 2020;10:12584. [PMID: 32724082 DOI: 10.1038/s41598-020-69358-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Sripongpun P, Pongpaibul A, Charatcharoenwitthaya P. Value and risk of percutaneous liver biopsy in patients with cirrhosis and clinical suspicion of autoimmune hepatitis. BMJ Open Gastroenterol 2021;8:e000701. [PMID: 34362759 DOI: 10.1136/bmjgast-2021-000701] [Reference Citation Analysis]
5 Sun K, Ma S, Tian S, Zhang M, Liu Y, Li B, Zhou X, Zheng X, Zhou X, Wang L, Han Y. An enhanced level of LAMP-2A participates in CD4+T cell hyperactivity in patients with primary biliary cholangitis. Ann Transl Med 2021;9:101. [PMID: 33569403 DOI: 10.21037/atm-20-2427] [Reference Citation Analysis]
6 Ito T, Ishigami M, Morooka H, Yamamoto K, Imai N, Ishizu Y, Honda T, Nishimura D, Tada T, Yasuda S, Toyoda H, Kumada T, Fujishiro M. The albumin-bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC. Sci Rep 2020;10:17812. [PMID: 33082429 DOI: 10.1038/s41598-020-74732-3] [Reference Citation Analysis]
7 Parés A, Shiffman M, Vargas V, Invernizzi P, Malecha ES, Liberman A, MacConell L, Hirschfield G. Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. Liver Int 2020;40:1121-9. [PMID: 32145129 DOI: 10.1111/liv.14429] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
8 Lachiondo-Ortega S, Mercado-Gómez M, Serrano-Maciá M, Lopitz-Otsoa F, Salas-Villalobos TB, Varela-Rey M, Delgado TC, Martínez-Chantar ML. Ubiquitin-Like Post-Translational Modifications (Ubl-PTMs): Small Peptides with Huge Impact in Liver Fibrosis. Cells 2019;8:E1575. [PMID: 31817258 DOI: 10.3390/cells8121575] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
9 Düll MM, Kremer AE. Treatment of Pruritus Secondary to Liver Disease. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0713-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
10 Shimoyama S, Kawata K, Ohta K, Chida T, Suzuki T, Tsuneyama K, Shimoda S, Kurono N, Leung PSC, Gershwin ME, Suda T, Kobayashi Y. Ursodeoxycholic acid impairs liver-infiltrating T-cell chemotaxis through IFN-γ and CX3CL1 production in primary biliary cholangitis. Eur J Immunol 2021;51:1519-30. [PMID: 33710617 DOI: 10.1002/eji.202048589] [Reference Citation Analysis]
11 Schulz M, Wilde AB, Demir M, Müller T, Tacke F, Wree A. Shear wave elastography and shear wave dispersion imaging in primary biliary cholangitis-a pilot study. Quant Imaging Med Surg 2022;12:1235-42. [PMID: 35111619 DOI: 10.21037/qims-21-657] [Reference Citation Analysis]
12 Cançado GGL, Braga MH, Ferraz MLG, Villela-Nogueira CA, Terrabuio DRB, Cançado ELR, Nardelli MJ, Faria LC, de Faria Gomes NM, Oliveira EMG, Rotman V, Oliveira MB, da Cunha SMCF, Cunha-Silva M, Mendes LSC, Ivantes CAP, Codes L, de Almeida E Borges VF, de Lima Pace FH, Pessoa MG, Signorelli IV, Coral GP, Bittencourt PL, Levy C, Couto CA; Members of the Brazilian Cholestasis Study Group Consortium. Anti-mitochondrial Antibody-Negative Primary Biliary Cholangitis Is Part of the Same Spectrum of Classical Primary Biliary Cholangitis. Dig Dis Sci 2021. [PMID: 34181166 DOI: 10.1007/s10620-021-07122-y] [Reference Citation Analysis]
13 Aguilar MT, Chascsa DM. Update on Emerging Treatment Options for Primary Biliary Cholangitis. Hepat Med 2020;12:69-77. [PMID: 32547264 DOI: 10.2147/HMER.S205431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 2021;51:725-49. [PMID: 34228859 DOI: 10.1111/hepr.13678] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Van Haele M, Snoeck J, Roskams T. Human Liver Regeneration: An Etiology Dependent Process. Int J Mol Sci 2019;20:E2332. [PMID: 31083462 DOI: 10.3390/ijms20092332] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
16 Zhang X, Xie QX, Zhao DM. Negative conversion of autoantibody profile in chronic hepatitis B: A case report. World J Clin Cases 2021; 9(5): 1196-1203 [PMID: 33644184 DOI: 10.12998/wjcc.v9.i5.1196] [Reference Citation Analysis]
17 Trivedi HD, Danford CJ, Goyes D, Bonder A. Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges. Clin Exp Gastroenterol 2020;13:17-24. [PMID: 32021374 DOI: 10.2147/CEG.S204638] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Trauner M, Nevens F, Shiffman ML, Drenth JPH, Bowlus CL, Vargas V, Andreone P, Hirschfield GM, Pencek R, Malecha ES, Macconell L, Shapiro D. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. The Lancet Gastroenterology & Hepatology 2019;4:445-53. [DOI: 10.1016/s2468-1253(19)30094-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 17] [Article Influence: 17.7] [Reference Citation Analysis]
19 Han W, Huang C, Zhang Q, Tao S, Hu X, Xu J, Jiang R, Xu B, Liu Y, Hou J. Alterations in gut microbiota and elevated serum bilirubin in primary biliary cholangitis patients treated with ursodeoxycholic acid. Eur J Clin Invest 2021;:e13714. [PMID: 34800290 DOI: 10.1111/eci.13714] [Reference Citation Analysis]
20 Carrion AF, Lindor KD, Levy C. Safety of fibrates in cholestatic liver diseases. Liver Int 2021;41:1335-43. [PMID: 33751787 DOI: 10.1111/liv.14871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Younossi ZM, Bernstein D, Shiffman ML, Kwo P, Kim WR, Kowdley KV, Jacobson IM. Diagnosis and Management of Primary Biliary Cholangitis. Am J Gastroenterol 2019;114:48-63. [DOI: 10.1038/s41395-018-0390-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
22 Zhao DT, Liu YM, Han Y, Zhang HP, Zhao Y, Yan HP. Fluctuations of antimitochondrial antibodies and anti-gp210 antibody in a patient with primary biliary cholangitis and Sjögren syndrome with subsequent autoimmune hemolytic anemia: A case report. Medicine (Baltimore) 2020;99:e18856. [PMID: 32011506 DOI: 10.1097/MD.0000000000018856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Zheng W, Jiang F, Shan J, Wang Y, Jia Y, Guo Q, Lou J, Zhao Y. Levels of serum IgG subclasses in patients with liver disease: A retrospective study. Exp Ther Med 2021;21:45. [PMID: 33273974 DOI: 10.3892/etm.2020.9476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Poyatos E, Morandeira F, Climent J, Mas V, Castellote J, Bas J. Detection of anti-mitochondrial 2-oxoacid dehydrogenase complex subunit's antibodies for the diagnosis of primary biliary cholangitis. Clin Immunol 2021;:108749. [PMID: 33945872 DOI: 10.1016/j.clim.2021.108749] [Reference Citation Analysis]
25 Tanaka A. PBC: No Longer a Western Disease? Clin Liver Dis (Hoboken) 2020;16:227-30. [PMID: 33489092 DOI: 10.1002/cld.903] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zhang Q, Liu Z, Wu S, Duan W, Chen S, Ou X, You H, Kong Y, Jia J. Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis. Gastroenterol Res Pract. 2019;2019:8959103. [PMID: 31281353 DOI: 10.1155/2019/8959103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
27 Di Bisceglie AM, Watts GF, Lavin P, Yu M, Bai R, Liu L. Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia. Lipids Health Dis 2020;19:239. [PMID: 33183320 DOI: 10.1186/s12944-020-01406-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 He C, Yang Y, Zheng K, Chen Y, Liu S, Li Y, Han Q, Zhao RC, Wang L, Zhang F. Mesenchymal stem cell-based treatment in autoimmune liver diseases: underlying roles, advantages and challenges. Ther Adv Chronic Dis 2021;12:2040622321993442. [PMID: 33633826 DOI: 10.1177/2040622321993442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Sultana H, Komai M, Shirakawa H. The Role of Vitamin K in Cholestatic Liver Disease. Nutrients 2021;13:2515. [PMID: 34444675 DOI: 10.3390/nu13082515] [Reference Citation Analysis]
30 Kawata K, Joshita S, Shimoda S, Yamashita Y, Yamashita M, Kitsugi K, Takatori S, Ohta K, Ito J, Shimoyama S, Noritake H, Suda T, Harada K. The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis. Hepatol Res 2021;51:80-9. [PMID: 33080094 DOI: 10.1111/hepr.13584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance From the American Association for the Study of Liver Diseases. Clinical Liver Disease 2020;15:1-2. [DOI: 10.1002/cld.874] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
32 Tanaka A. Current understanding of primary biliary cholangitis. Clin Mol Hepatol 2021;27:1-21. [PMID: 33264835 DOI: 10.3350/cmh.2020.0028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Bauer A, Habior A. Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis. Front Immunol 2022;13:885229. [DOI: 10.3389/fimmu.2022.885229] [Reference Citation Analysis]
34 Kremer AE, Mayo MJ, Hirschfield G, Levy C, Bowlus CL, Jones DE, Steinberg A, McWherter CA, Choi YJ. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver Int 2021. [PMID: 34403559 DOI: 10.1111/liv.15039] [Reference Citation Analysis]
35 Golpanian RS, Yosipovitch G, Levy C. Use of Butorphanol as Treatment for Cholestatic Itch. Dig Dis Sci 2021;66:1693-9. [PMID: 32556969 DOI: 10.1007/s10620-020-06392-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Wang Y, Guo P, Zhang Y, Liu L, Yan R, Yuan Z, Song Y. Joint Analysis of Genetic Correlation, Mendelian Randomization and Colocalization Highlights the Bi-Directional Causal Association Between Hypothyroidism and Primary Biliary Cirrhosis. Front Genet 2021;12:753352. [PMID: 34671386 DOI: 10.3389/fgene.2021.753352] [Reference Citation Analysis]
37 Zandanell S, Strasser M, Feldman A, Strebinger G, Aigner G, Niederseer D, Laimer M, Mussnig B, Paulweber B, Datz C, Aigner E. Similar clinical outcome of AMA immunoblot-M2-negative compared to immunoblot-positive subjects over six years of follow-up. Postgrad Med 2021;133:291-8. [PMID: 33538618 DOI: 10.1080/00325481.2021.1885945] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Huang C, Han W, Wang C, Liu Y, Chen Y, Duan Z. Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis. Dis Markers 2019;2019:9121207. [PMID: 31737133 DOI: 10.1155/2019/9121207] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
39 Safarikia S, Carpino G, Overi D, Cardinale V, Venere R, Franchitto A, Onori P, Alvaro D, Gaudio E. Distinct EpCAM-Positive Stem Cell Niches Are Engaged in Chronic and Neoplastic Liver Diseases. Front Med (Lausanne) 2020;7:479. [PMID: 32984373 DOI: 10.3389/fmed.2020.00479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Lim TS, Kim JK. Is liver biopsy still useful in the era of non-invasive tests? Clin Mol Hepatol 2020;26:302-4. [PMID: 32646204 DOI: 10.3350/cmh.2020.0081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Turvey SL, Saxinger L, Mason AL. Apples to Apples? A Comparison of Real-World Tolerability of Antiretrovirals in Patients with Human Immunodeficiency Virus Infection and Patients with Primary Biliary Cholangitis. Viruses 2022;14:516. [DOI: 10.3390/v14030516] [Reference Citation Analysis]
42 Sedki M, Fonseca N, Santiago P, Diaz L, Garcia-Buitrago M, Mirsaeidi M, Levy C. Hepatic Sarcoidosis: Natural History and Management Implications. Front Med (Lausanne) 2019;6:232. [PMID: 31737633 DOI: 10.3389/fmed.2019.00232] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
43 John BV, Khakoo NS, Schwartz KB, Aitchenson G, Levy C, Dahman B, Deng Y, Goldberg DS, Martin P, Kaplan DE, Taddei TH. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. Am J Gastroenterol 2021;116:1913-23. [PMID: 33989225 DOI: 10.14309/ajg.0000000000001280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Lee BT, Tana MM, Kahn JA, Dara L. We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases. Hepatology 2021. [PMID: 34056734 DOI: 10.1002/hep.31985] [Reference Citation Analysis]
45 Levy C. Primary Biliary Cholangitis Guidance Update: Implications for Liver Transplantation: Liver Transplantation. Liver Transpl 2018;24:1508-11. [DOI: 10.1002/lt.25321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Zhao SX, Li WC, Fu N, Zhou GD, Liu SH, Jiang LN, Zhang YG, Wang RQ, Nan YM, Zhao JM. Emperipolesis mediated by CD8+ T cells correlates with biliary epithelia cell injury in primary biliary cholangitis. J Cell Mol Med 2020;24:1268-75. [PMID: 31851780 DOI: 10.1111/jcmm.14752] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Harms MH, de Veer RC, Lammers WJ, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Trivedi PJ, Hirschfield GM, Pares A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Hansen BE, Buuren HRV, van der Meer AJ. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut 2020;69:1502-9. [PMID: 31843787 DOI: 10.1136/gutjnl-2019-319057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
48 Drazilova S, Babinska I, Gazda J, Halanova M, Janicko M, Kucinsky B, Safcak D, Martinkova D, Tarbajova L, Cekanova A, Jarcuska P; Eastern Slovakia PBC Group. Epidemiology and clinical course of primary biliary cholangitis in Eastern Slovakia. Int J Public Health 2020;65:683-91. [PMID: 32500239 DOI: 10.1007/s00038-020-01391-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Freedman BL, Danford CJ, Patwardhan V, Bonder A. Treatment of Overlap Syndromes in Autoimmune Liver Disease: A Systematic Review and Meta-Analysis. J Clin Med 2020;9:E1449. [PMID: 32414025 DOI: 10.3390/jcm9051449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
50 John BV, Aitcheson G, Schwartz KB, Khakoo NS, Dahman B, Deng Y, Goldberg D, Martin P, Taddei TH, Levy C, Kaplan DE. Male Sex Is Associated With Higher Rates of Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis. Hepatology 2021;74:879-91. [PMID: 33636012 DOI: 10.1002/hep.31776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Sakai Y, Fukunishi S, Takamura M, Inoue O, Takashima S, Usui S, Seki A, Nasti A, Ho TTB, Kawaguchi K, Asai A, Tsuchimoto Y, Yamashita T, Yamashita T, Mizukoshi E, Honda M, Imai Y, Yoshimura K, Murayama T, Wada T, Harada K, Higuchi K, Kaneko S. Regenerative Therapy for Liver Cirrhosis Based on Intrahepatic Arterial Infusion of Autologous Subcutaneous Adipose Tissue-Derived Regenerative (Stem) Cells: Protocol for a Confirmatory Multicenter Uncontrolled Clinical Trial. JMIR Res Protoc 2020;9:e17904. [PMID: 32229470 DOI: 10.2196/17904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Jeong HM, Kim DJ. Bone Diseases in Patients with Chronic Liver Disease. Int J Mol Sci. 2019;20. [PMID: 31480433 DOI: 10.3390/ijms20174270] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
53 Sakai T, Kondo M, Kawana Y, Inoue R. A case of neuromyelitis optica spectrum disorders associated with primary biliary cholangitis: a twelve year follow-up study. Rinsho Shinkeigaku. [DOI: 10.5692/clinicalneurol.cn-001668] [Reference Citation Analysis]
54 Bauer A, Habior A, Wieszczy P, Gawel D. Analysis of Autoantibodies against Promyelocytic Leukemia Nuclear Body Components and Biochemical Parameters in Sera of Patients with Primary Biliary Cholangitis. Diagnostics (Basel) 2021;11:587. [PMID: 33805158 DOI: 10.3390/diagnostics11040587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Laschtowitz A, de Veer RC, Van der Meer AJ, Schramm C. Diagnosis and treatment of primary biliary cholangitis. United European Gastroenterol J 2020;8:667-74. [PMID: 32299307 DOI: 10.1177/2050640620919585] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Duszynski CC, Avati V, Lapointe AP, Scholkmann F, Dunn JF, Swain MG. Near-Infrared Spectroscopy Reveals Brain Hypoxia and Cerebrovascular Dysregulation in Primary Biliary Cholangitis. Hepatology 2020;71:1408-20. [PMID: 31535726 DOI: 10.1002/hep.30920] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
57 Louie JS, Grandhe S, Matsukuma K, Bowlus CL. Primary Biliary Cholangitis: A Brief Overview. Clin Liver Dis (Hoboken) 2020;15:100-4. [PMID: 32257120 DOI: 10.1002/cld.867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Yang Z, Liang Y. New-onset primary biliary cholangitis in anti-mitochondrial antibody-positive patients may be underestimated without liver biopsy. J Intern Med 2020;287:580-1. [PMID: 32034820 DOI: 10.1111/joim.13023] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Punia S, Juran BD, Ali AH, Schlicht EM, Moore RM, Sun Z, Lazaridis KN. Evaluation of circulating cell-free DNA in cholestatic liver disease using liver-specific methylation markers. BMC Gastroenterol 2021;21:149. [PMID: 33794792 DOI: 10.1186/s12876-021-01741-5] [Reference Citation Analysis]
60 Düll MM, Kremer AE. Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease. Curr Hepatology Rep 2020;19:86-95. [DOI: 10.1007/s11901-020-00517-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Molinaro A, Marschall HU. Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders. Biochem Soc Trans 2022:BST20210658. [PMID: 35191955 DOI: 10.1042/BST20210658] [Reference Citation Analysis]
62 Lytvyak E, Niazi M, Pai R, He D, Zhang G, Hübscher SG, Mason AL. Combination antiretroviral therapy improves recurrent primary biliary cholangitis following liver transplantation. Liver Int 2021;41:1879-83. [PMID: 34008271 DOI: 10.1111/liv.14964] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Liu C, Wang YL, Yang YY, Zhang NP, Niu C, Shen XZ, Wu J. Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. FASEB J 2021;35:e21871. [PMID: 34473374 DOI: 10.1096/fj.202100939R] [Reference Citation Analysis]
64 Liu Y, Tian S, Jia G, Han Z, Guo C, Shang Y, Han Y. Symptoms Burden and Health-related Quality of Life in Chinese Patients with Primary Biliary Cholangitis. J Clin Transl Hepatol 2021;9:860-7. [PMID: 34966649 DOI: 10.14218/JCTH.2020.00119] [Reference Citation Analysis]
65 Kouroumalis E, Voumvouraki A, Augoustaki A, Samonakis DN. Autophagy in liver diseases. World J Hepatol 2021; 13(1): 6-65 [PMID: 33584986 DOI: 10.4254/wjh.v13.i1.6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
66 Liwinski T, Heinemann M, Schramm C. The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts. Semin Immunopathol 2022. [PMID: 35536431 DOI: 10.1007/s00281-022-00936-6] [Reference Citation Analysis]
67 Bosch DE, Zen Y, Boukhar SA, Liu Y, Cheng L, Yeh MM. Hepatocellular carcinoma in primary sclerosing cholangitis and primary biliary cholangitis: a clinical and pathological study in an uncommon but emerging setting. Virchows Arch 2021. [PMID: 34414507 DOI: 10.1007/s00428-021-03183-6] [Reference Citation Analysis]
68 Mago S, Wu GY. Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis Overlap Syndrome: A Review. J Clin Transl Hepatol 2020;8:336-46. [PMID: 33083257 DOI: 10.14218/JCTH.2020.00036] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Green EW, Kahl L, Jou JH. Systemic Sclerosis and the Liver. Clin Liver Dis (Hoboken) 2021;18:76-80. [PMID: 34584672 DOI: 10.1002/cld.1074] [Reference Citation Analysis]
70 Roberts SB, Ismail M, Kanagalingam G, Mason AL, Swain MG, Vincent C, Yoshida EM, Tsien C, Flemming JA, Janssen HLA, Hirschfield GM, Hansen BE, Gulamhusein AF; Canadian Network for Autoimmune Liver Disease. Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis. Hepatol Commun 2020;4:1332-45. [PMID: 32923836 DOI: 10.1002/hep4.1518] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
71 Ehsan NA, Elsabaawy MM, Sweed DM, Karman EA, Abdelsameea E, Mohamed AA. Role of liver biopsy in management of liver diseases without hepatic nodules following end of the interferon era: experience of a tertiary referral center. Clin Exp Med 2022. [PMID: 35262836 DOI: 10.1007/s10238-022-00797-1] [Reference Citation Analysis]
72 Ding D, Xuan G, Hu Y, Yu J, Liu Y, Guo G, Ma S, Yang F, Tian S, Ma G, Chen L, Zhou X, Shang Y, Han Y. Immunoglobulin M: A Neglected Serum Biomarker in Treatment-Naive Primary Biliary Cholangitis With Normal Alkaline Phosphatase. Hepatol Commun 2022. [PMID: 35182047 DOI: 10.1002/hep4.1907] [Reference Citation Analysis]
73 Morgan MA, Sundaram KM. Primary biliary cholangitis: review for radiologists. Abdom Radiol (NY) 2021. [PMID: 34743232 DOI: 10.1007/s00261-021-03335-x] [Reference Citation Analysis]
74 Chen S, Lv T, Sun G, Li S, Duan W, Zhang C, Jin H, Tian D, Li M, Shan S, Ma H, Ou X, You H, Zhang D, Jia J. Reciprocal alterations in circulating and hepatic gamma-delta T cells in patients with primary biliary cholangitis. Hepatol Int 2022. [PMID: 35028922 DOI: 10.1007/s12072-021-10267-7] [Reference Citation Analysis]
75 Becker Y, Loignon RC, Julien AS, Marcoux G, Allaeys I, Lévesque T, Rollet-Labelle E, Benk-Fortin H, Cloutier N, Melki I, Eder L, Wagner É, Pelletier M, Hajj HE, Tremblay MÈ, Belleannée C, Hébert MJ, Dieudé M, Rauch J, Fortin PR, Boilard E. Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations. Sci Rep 2019;9:4530. [PMID: 30872710 DOI: 10.1038/s41598-019-40900-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
76 Sorda JA, González Ballerga E, Barreyro FJ, Avagnina A, Carballo P, Paes de Lima A, Daruich J. Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up. Aliment Pharmacol Ther 2021;54:1202-12. [PMID: 34587309 DOI: 10.1111/apt.16618] [Reference Citation Analysis]
77 Sayar S, Gokcen P, Aykut H, Adali G, Doganay HL, Ozdil K. Can simple Non-Invasive Fibrosis Models Determine Prognostic Indicators (Fibrosis and Treatment Response) of Primary Biliary Cholangitis? Sisli Etfal Hastan Tip Bul 2021;55:412-8. [PMID: 34712085 DOI: 10.14744/SEMB.2021.95825] [Reference Citation Analysis]
78 Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Reference Citation Analysis]
79 Taylor SA, Assis DN, Mack CL. The Contribution of B Cells in Autoimmune Liver Diseases. Semin Liver Dis 2019;39:422-31. [PMID: 31226726 DOI: 10.1055/s-0039-1688751] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
80 Zhang L, Ding D, Yu L, Qi H, Han C, Jiang J, Jiang J. Primary biliary cirrhosis associated with myasthenia gravis after postpartum: a case report. J Med Case Rep 2021;15:498. [PMID: 34627357 DOI: 10.1186/s13256-021-03092-x] [Reference Citation Analysis]
81 Fujinaga Y, Namisaki T, Moriya K, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Akahane T, Okura Y, Sato S, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Mashitani T, Ishida K, Ogawa H, Takagi H, Noguchi R, Mitoro A, Yamao J, Yoshiji H. Identification of clinical risk factors for histological progression of primary biliary cholangitis. Hepatol Res 2019;49:1015-25. [DOI: 10.1111/hepr.13355] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
82 Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology 2021. [PMID: 34431119 DOI: 10.1002/hep.32117] [Reference Citation Analysis]
83 Wilde AB, Lieb C, Leicht E, Greverath LM, Steinhagen LM, Wald de Chamorro N, Petersen J, Hofmann WP, Hinrichsen H, Heyne R, Berg T, Naumann U, Schwenzer J, Vermehren J, Geier A, Tacke F, Müller T. Real-World Clinical Management of Patients with Primary Biliary Cholangitis-A Retrospective Multicenter Study from Germany. J Clin Med 2021;10:1061. [PMID: 33806503 DOI: 10.3390/jcm10051061] [Reference Citation Analysis]
84 Levien TL, Baker DE. Formulary Drug Review: Odevixibat. Hosp Pharm. [DOI: 10.1177/00185787211069036] [Reference Citation Analysis]
85 Corpechot C, Poupon R, Chazouillères O. New treatments/targets for primary biliary cholangitis. JHEP Rep 2019;1:203-13. [PMID: 32039371 DOI: 10.1016/j.jhepr.2019.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
86 Hasegawa S, Yoneda M, Kurita Y, Nogami A, Honda Y, Hosono K, Nakajima A. Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents. Drugs 2021;81:1181-92. [PMID: 34142342 DOI: 10.1007/s40265-021-01545-7] [Reference Citation Analysis]
87 Hayashi M, Abe K, Fujita M, Takahashi A, Hashimoto Y, Ohira H. Serum Gas6 and Axl as non-invasive biomarkers of advanced histological stage in primary biliary cholangitis. Hepatol Res 2020;50:1337-46. [PMID: 32885557 DOI: 10.1111/hepr.13568] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Chen VL, Du X, Chen Y, Kuppa A, Handelman SK, Vohnoutka RB, Peyser PA, Palmer ND, Bielak LF, Halligan B, Speliotes EK. Genome-wide association study of serum liver enzymes implicates diverse metabolic and liver pathology. Nat Commun 2021;12:816. [PMID: 33547301 DOI: 10.1038/s41467-020-20870-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
89 Chascsa DMH, Lindor KD. Emerging therapies for PBC. J Gastroenterol 2020;55:261-72. [PMID: 31970467 DOI: 10.1007/s00535-020-01664-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
90 Sivakumar M, Gandhi A, Shakweh E, Li YM, Safinia N, Smith BC, Marshall A, Turner L, Mukhopadhya A, Haboubi HN, Vincent R, Tan HK, Alrubaiy L, Jones DEJ. Widespread gaps in the quality of care for primary biliary cholangitis in UK. Frontline Gastroenterol 2022;13:32-8. [PMID: 34966531 DOI: 10.1136/flgastro-2020-101713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Xiang X, Yang X, Shen M, Huang C, Liu Y, Fan X, Yang L. Ursodeoxycholic Acid at 18-22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis. Can J Gastroenterol Hepatol 2021;2021:6691425. [PMID: 33542908 DOI: 10.1155/2021/6691425] [Reference Citation Analysis]
92 Robles-Díaz M, Nezic L, Vujic-Aleksic V, Björnsson ES. Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review. Front Pharmacol 2021;12:744488. [PMID: 34776963 DOI: 10.3389/fphar.2021.744488] [Reference Citation Analysis]
93 Lv T, Chen S, Li M, Zhang D, Kong Y, Jia J. Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1423-34. [PMID: 33141955 DOI: 10.1111/jgh.15329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Han Y, Bian Z, Yang S, Wang C, Li L, Yang Y, Ansari AA, Gershwin ME, Zeng X, Lian Z, Zhao Z. Single-Cell Characterization of Hepatic CD8+ T Cells in a Murine Model of Primary Biliary Cholangitis. Front Immunol 2022;13:860311. [DOI: 10.3389/fimmu.2022.860311] [Reference Citation Analysis]
95 Heijke R, Ahmad A, Frodlund M, Wirestam L, Dahlström Ö, Dahle C, Kechagias S, Sjöwall C. Usefulness of Clinical and Laboratory Criteria for Diagnosing Autoimmune Liver Disease among Patients with Systemic Lupus Erythematosus: An Observational Study. J Clin Med 2021;10:3820. [PMID: 34501268 DOI: 10.3390/jcm10173820] [Reference Citation Analysis]
96 Gallucci GM, Trottier J, Hemme C, Assis DN, Boyer JL, Barbier O, Ghonem NS. Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis. Hepatol Commun 2021;5:2035-51. [PMID: 34558841 DOI: 10.1002/hep4.1787] [Reference Citation Analysis]
97 Baiocchi L, Zhou T, Liangpunsakul S, Ilaria L, Milana M, Meng F, Kennedy L, Kusumanchi P, Yang Z, Ceci L, Glaser S, Francis H, Alpini G. Possible application of melatonin treatment in human diseases of the biliary tract. Am J Physiol Gastrointest Liver Physiol 2019;317:G651-60. [PMID: 31509434 DOI: 10.1152/ajpgi.00110.2019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
98 Dokmak A, Trivedi HD, Bonder A, Wolf J. Pregnancy in Chronic Liver Disease: Before and After Transplantation. Ann Hepatol 2021;:100557. [PMID: 34656772 DOI: 10.1016/j.aohep.2021.100557] [Reference Citation Analysis]
99 Zandanell S, Strasser M, Feldman A, Tevini J, Strebinger G, Niederseer D, Pohla-Gubo G, Huber-Schönauer U, Ruhaltinger S, Paulweber B, Datz C, Felder TK, Aigner E. Low rate of new-onset primary biliary cholangitis in a cohort of anti-mitochondrial antibody-positive subjects over six years of follow-up. J Intern Med 2020;287:395-404. [PMID: 31802567 DOI: 10.1111/joim.13005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
100 Galoosian A, Hanlon C, Zhang J, Holt EW, Yimam KK. Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches. J Clin Transl Hepatol 2020;8:49-60. [PMID: 32274345 DOI: 10.14218/JCTH.2019.00049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
101 Johnson AM, Akpan EJ, Kale S, Patel A. A Rare Case Presentation: Diagnosing Primary Biliary Cholangitis in a Male Patient With Concomitant Type 1 Diabetes. Cureus 2021;13:e16109. [PMID: 34367753 DOI: 10.7759/cureus.16109] [Reference Citation Analysis]
102 Mazzetti M, Marconi G, Mancinelli M, Benedetti A, Marzioni M, Maroni L. The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities. J Clin Med 2021;10:1763. [PMID: 33919600 DOI: 10.3390/jcm10081763] [Reference Citation Analysis]
103 Cançado GGL, Couto CA, Guedes LV, Braga MH, Terrabuio DRB, Cançado ELR, Ferraz MLG, Villela-nogueira CA, Nardelli MJ, Faria LC, Oliveira EMGD, Rotman V, Mazo DFDC, Borges VFDAE, Mendes LSC, Codes L, Pessoa MG, Signorelli IV, Levy C, Bittencourt PL. Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study. Front Pharmacol 2022;12:818089. [DOI: 10.3389/fphar.2021.818089] [Reference Citation Analysis]
104 Gao L, Wang L, Woo E, He X, Yang G, Bowlus C, Leung PSC, Gershwin ME. Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends. Clin Rev Allergy Immunol. 2019;. [PMID: 31713023 DOI: 10.1007/s12016-019-08772-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
105 Sultan K, Petkar M, Derbala M. Florid biliary duct lesions in an AMA -positive patient in absence of cholestatic liver biochemistry. Journal of Autoimmunity 2019;101:153-5. [DOI: 10.1016/j.jaut.2019.04.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
106 Bauer A, Habior A, Gawel D. Diagnostic and Clinical Value of Specific Autoantibodies against Kelch-like 12 Peptide and Nuclear Envelope Proteins in Patients with Primary Biliary Cholangitis. Biomedicines 2022;10:801. [DOI: 10.3390/biomedicines10040801] [Reference Citation Analysis]
107 Sasaki M, Sato Y, Nakanuma Y. Interferon-induced protein with tetratricopeptide repeats 3 may be a key factor in primary biliary cholangitis. Sci Rep 2021;11:11413. [PMID: 34075171 DOI: 10.1038/s41598-021-91016-6] [Reference Citation Analysis]
108 Amir M, Parekh SM. Classic Autoimmune Liver Disorders and Celiac Hepatitis. Clin Liver Dis (Hoboken) 2021;17:347-52. [PMID: 34136140 DOI: 10.1002/cld.1056] [Reference Citation Analysis]
109 Gao Y, Li L, Li B, Zhan Y. Response Rate and Impact on Lipid Profiles of Obeticholic Acid Treatment for Patients with Primary Biliary Cholangitis: A Meta-Analysis. Can J Gastroenterol Hepatol 2021;2021:8829510. [PMID: 33511089 DOI: 10.1155/2021/8829510] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Manzo C, Maslinska M, Castagna A, Hysa E, Merante A, Milchert M, Gravina T, Sargin B, Natale M, Ruberto C, Ruotolo G. Antimitochondrial Antibodies and Primary Biliary Cholangitis in Patients with Polymyalgia Rheumatica/Giant Cell Arteritis. Medicina (Kaunas) 2021;57:350. [PMID: 33917502 DOI: 10.3390/medicina57040350] [Reference Citation Analysis]
111 You H, Ma X, Efe C, Wang G, Jeong SH, Abe K, Duan W, Chen S, Kong Y, Zhang D, Wei L, Wang FS, Lin HC, Yang JM, Tanwandee T, Gani RA, Payawal DA, Sharma BC, Hou J, Yokosuka O, Dokmeci AK, Crawford D, Kao JH, Piratvisuth T, Suh DJ, Lesmana LA, Sollano J, Lau G, Sarin SK, Omata M, Tanaka A, Jia J. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int 2022. [PMID: 35119627 DOI: 10.1007/s12072-021-10276-6] [Reference Citation Analysis]
112 Ueno K, Aiba Y, Hitomi Y, Shimoda S, Nakamura H, Gervais O, Kawai Y, Kawashima M, Nishida N, Kohn SS, Kojima K, Katsushima S, Naganuma A, Sugi K, Komatsu T, Mannami T, Matsushita K, Yoshizawa K, Makita F, Nikami T, Nishimura H, Kouno H, Kouno H, Ohta H, Komura T, Tsuruta S, Yamauchi K, Kobata T, Kitasato A, Kuroki T, Abiru S, Nagaoka S, Komori A, Yatsuhashi H, Migita K, Ohira H, Tanaka A, Takikawa H, Nagasaki M, Tokunaga K, Nakamura M; PBC‐GWAS Consortium in Japan. Integrated GWAS and mRNA Microarray Analysis Identified IFNG and CD40L as the Central Upstream Regulators in Primary Biliary Cholangitis. Hepatol Commun 2020;4:724-38. [PMID: 32363322 DOI: 10.1002/hep4.1497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
113 Himoto T, Yamamoto S, Morimoto K, Tada S, Mimura S, Fujita K, Tani J, Morishita A, Masaki T. Clinical impact of antibodies to Sp100 on a bacterial infection in patients with primary biliary cholangitis. J Clin Lab Anal 2021;35:e24040. [PMID: 34623692 DOI: 10.1002/jcla.24040] [Reference Citation Analysis]
114 Harms MH, Hirschfield GM, Floreani A, Mayo MJ, Parés A, Liberman A, Malecha ES, Pencek R, MacConell L, Hansen BE. Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. JHEP Rep 2021;3:100191. [PMID: 33319187 DOI: 10.1016/j.jhepr.2020.100191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Yang L, Ling W, He D, Lu C, Ma L, Tang L, Luo Y, Chen S. Shear wave-based sound touch elastography in liver fibrosis assessment for patients with autoimmune liver diseases. Quant Imaging Med Surg 2021;11:1532-42. [PMID: 33816189 DOI: 10.21037/qims-20-521] [Reference Citation Analysis]
116 Ebadi M, Ip S, Lytvyak E, Asghari S, Rider E, Mason A, Montano-loza AJ. Vitamin D Is Associated with Clinical Outcomes in Patients with Primary Biliary Cholangitis. Nutrients 2022;14:878. [DOI: 10.3390/nu14040878] [Reference Citation Analysis]
117 Haldar D, Janmohamed A, Plant T, Davidson M, Norman H, Russell E, Serevina O, Chung K, Qamar K, Gunson B, Hansen B, Richter A, Trivedi PJ, Hirschfield GM. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis. Liver Int 2021;41:535-44. [PMID: 33022821 DOI: 10.1111/liv.14688] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
118 Huang P, Hou Y, Zou Y, Ye X, Yu R, Yang S. The Causal Effects of Primary Biliary Cholangitis on Thyroid Dysfunction: A Two-Sample Mendelian Randomization Study. Front Genet 2021;12:791778. [PMID: 34956333 DOI: 10.3389/fgene.2021.791778] [Reference Citation Analysis]
119 Tanaka A. Emerging novel treatments for autoimmune liver diseases. Hepatol Res 2019;49:489-99. [PMID: 30969002 DOI: 10.1111/hepr.13347] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
120 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 2021;56:593-619. [PMID: 34231046 DOI: 10.1007/s00535-021-01788-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
121 Pate J, Gutierrez JA, Frenette CT, Goel A, Kumar S, Manch RA, Mena EA, Pockros PJ, Satapathy SK, Yimam KK, Gish RG. Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. BMJ Open Gastroenterol 2019;6:e000256. [PMID: 30815273 DOI: 10.1136/bmjgast-2018-000256] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
122 John BV, Dahman B, Deng Y, Khakoo NS, Taddei TH, Kaplan DE, Levy C. Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis. Liver Int 2021. [PMID: 34614294 DOI: 10.1111/liv.15079] [Reference Citation Analysis]
123 Pericleous M, Kelly C, Odin JA, Kallis Y, McGee C, Sherlock J, Yonova I, de Lusignan S, Ala A. Clinical Ontologies Improve Case Finding of Primary Biliary Cholangitis in UK Primary and Secondary Care. Dig Dis Sci 2020;65:3143-58. [PMID: 31953628 DOI: 10.1007/s10620-019-06039-x] [Reference Citation Analysis]
124 Joshita S, Umemura T, Yamashita Y, Sugiura A, Yamazaki T, Fujimori N, Matsumoto A, Tanaka E. Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis. Hepatol Res 2019;49:1236-43. [PMID: 31077509 DOI: 10.1111/hepr.13361] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
125 Terziroli Beretta-Piccoli B, Stirnimann G, Mertens J, Semela D, Zen Y, Mazzucchelli L, Voreck A, Kolbus N, Merlo E, Di Bartolomeo C, Messina P, Cerny A, Costantini S, Vergani D, Mieli-Vergani G; Swiss PBC Cohort Study Group. Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines. J Autoimmun 2021;116:102578. [PMID: 33229138 DOI: 10.1016/j.jaut.2020.102578] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Abid H, Akoch I, Lahlali M, Lahmidani N, El Yousfi M, Benajah D, El Abkari M, Ibrahimi A. Primary Biliary Cholangitis: Predictors of Poor Response to Ursodeoxycholic Acid after 1 Year of Treatment in Moroccan Patients. JMSR. [DOI: 10.46327/msrjg.1.000000000000202] [Reference Citation Analysis]
127 Xiang B, Deng C, Qiu F, Li J, Li S, Zhang H, Lin X, Huang Y, Zhou Y, Su J, Lu M, Ma Y. Single cell sequencing analysis identifies genetics-modulated ORMDL3+ cholangiocytes having higher metabolic effects on primary biliary cholangitis. J Nanobiotechnology 2021;19:406. [PMID: 34872583 DOI: 10.1186/s12951-021-01154-2] [Reference Citation Analysis]
128 Gazda J, Drazilova S, Janicko M, Grgurevic I, Filipec Kanizaj T, Koller T, Bodorovska B, Bozin T, Mijic M, Rob Z, Mikolasevic I, Madir A, Kucinsky B, Jarcuska P. Prognostic Factors in Primary Biliary Cholangitis: A Retrospective Study of Joint Slovak and Croatian Cohort of 249 Patients. J Pers Med 2021;11:495. [PMID: 34205918 DOI: 10.3390/jpm11060495] [Reference Citation Analysis]
129 Antoszewska M, Spychalski P, Villadsen GE, Aagaard NKM. Treatment of intractable pruritus in patients with cholestasis with molecular adsorbents recirculating system dialysis: a case series. Prz Gastroenterol 2021;16:254-6. [PMID: 34584590 DOI: 10.5114/pg.2021.108992] [Reference Citation Analysis]
130 Amano N, Ikeda Y, Hayashida S, Takahashi S, Sato S, Murata A, Tsuzura H, Sato S, Shimada Y, Iijima K, Wada R, Nagahara A, Genda T. Prognostic significance of serum tyrosine concentration in patients with primary biliary cholangitis under ursodeoxycholic acid therapy. Hepatol Res 2020;50:214-23. [PMID: 31652380 DOI: 10.1111/hepr.13434] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]